What is MDR?
MDR stands for Medical Device Regulation — a comprehensive regulatory framework that governs the development, manufacturing, and distribution of medical devices within the European Union. The regulation was officially published in 2017 and became fully applicable on May 26, 2021, marking a significant shift in how medical devices are regulated and approved for market access.
The implementation of MDR was driven by several critical factors: enhanced patient safety through stricter requirements for clinical evidence and post-market surveillance; improved transparency through greater requirements for device traceability and information sharing; harmonized standards creating consistent regulatory requirements across all EU member states; and future-proofing to address emerging technologies and novel device types.
Key Changes Under MDR
1. Classification System Updates — MDR introduces more stringent classification rules, potentially moving devices to higher risk categories that require more rigorous clinical evidence and Notified Body involvement.
2. Enhanced Clinical Evidence Requirements — More comprehensive clinical data requirements, mandatory clinical investigations for high-risk devices, and stricter requirements for clinical evaluation reports (CERs).
3. Post-Market Surveillance (PMS) — Enhanced post-market surveillance requirements, mandatory post-market clinical follow-up (PMCF) for certain devices, and more detailed safety reporting obligations.
4. Unique Device Identification (UDI) — Implementation of UDI system for device traceability, enhanced labeling requirements, and improved device identification throughout the supply chain.
MDR Compliance Challenges
Technical Documentation — More comprehensive technical documentation requirements, enhanced risk management documentation, and stricter quality management system requirements.
Clinical Evidence — Difficulty in gathering sufficient clinical data for legacy devices, challenges in conducting new clinical studies, and complex requirements for clinical evaluation reports.
Notified Body Capacity — Limited availability of Notified Bodies, extended review timelines, and increased costs for conformity assessment.
The Impact on Different Stakeholders
Medical Device Manufacturers face increased regulatory burden and costs, need for enhanced quality management systems, and requirement for more comprehensive clinical data.
Healthcare Providers benefit from improved device safety and performance information, better traceability of devices, and enhanced post-market surveillance data.
Patients gain greater confidence in device safety, improved access to device information, and enhanced protection through stricter regulations.
How Consulting Services Can Help
Navigating MDR compliance requires specialized expertise and strategic planning. Professional consulting services can provide gap analysis of current compliance status, development of MDR transition roadmaps, risk assessment and mitigation strategies, preparation of enhanced technical documentation, clinical evaluation report development, QMS gap analysis and improvement, clinical data gap analysis, PMCF study design and implementation, preparation for Notified Body audits, and communication strategy with regulatory bodies.
FDA Perspective on MDR
The FDA recognizes the importance of international harmonization in medical device regulation. While the FDA operates under different regulatory frameworks, there are areas of alignment between FDA requirements and MDR: both emphasize the importance of clinical evidence, risk-based classification systems, post-market surveillance requirements, and quality management system requirements.
Conclusion
MDR represents a fundamental shift in medical device regulation that requires careful planning and strategic implementation. Successfully navigating MDR compliance requires comprehensive understanding of regulatory requirements, strategic planning and resource allocation, expertise in clinical evidence development, robust quality management systems, and effective stakeholder communication.
This post provides general information about MDR requirements. For specific compliance guidance tailored to your organization, please contact our consulting team for personalized support.
Congratulations to BSC®’s David Maislin, Alex Breno, and our friends at 3Spine on their recent publication!
The article lays out the protocol for the pivotal IDE trial behind 3Spine's MOTUS® lumbar Total Joint Replacement, the first device built to restore both disc and facet joint function without sacrificing motion.
WHAT CLIENTS SAY
“They listen the first time. I’ve never had to go back and respell out what I needed."
”They work to understand the problem and leverage the information that is already there.”
Former FDA Regulator
WHAT CLIENTS SAY
"Battle ground tested."
"There is nothing that David and team haven’t seen over the years – the good, bad, and ugly.”
Vice President, Clinical Operations
WHAT CLIENTS SAY
"Get stuff done when you have to do something no one else has done before."
"They aren’t afraid to tackle difficult scenarios in compressed timelines."
CEO, Medical Device Company
Regulatory-first biostatistics
Support built specifically for FDA-facing programs, from early feasibility through submission and post-market requirements.
Direct communication, faster turn around
Our biostatisticians write the SAP and run the analysis. One person owns both — no separate programmer, no project manager in between.
Versatile Solutions
Engage us for a focused analysis or a full submission, We size the work to the problem.
Proven FDA Experience
Hands-On Experience with FDA Pathways, statistical reviews, and regular interactions, reducing risk and rework.










